The effect of exenatide re-exposure on safety and efficacyFALUDI, Peter; BRODOWS, Robert; BURGER, Jude et al.Peptides (New York, NY. 1980). 2009, Vol 30, Num 9, pp 1771-1774, issn 0196-9781, 4 p.Article

Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemiaJIZI JIN; KANG, Hye-Min; JUNYANG JUNG et al.Neuroreport (Oxford). 2014, Vol 25, Num 1, pp 65-70, issn 0959-4965, 6 p.Article

Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivoXUEMIN ZHENG; YING LI; GANG FU et al.Peptides (New York, NY. 1980). 2011, Vol 32, Num 5, pp 964-970, issn 0196-9781, 7 p.Article

Exenatide : effect of injection time on postprandial glucose in patients with Type 2 diabetesLINNEBJERG, H; KOTHARE, P. A; SKRIVANEK, Z et al.Diabetic medicine. 2006, Vol 23, Num 3, pp 240-245, issn 0742-3071, 6 p.Article

Extending the Reach of Exendin-4: New Pathways in the Control of Body Weight and Glucose HomeostasisGOOD, Deborah J.Endocrinology (Philadelphia). 2012, Vol 153, Num 5, pp 2051-2053, issn 0013-7227, 3 p.Article

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopeniaNUCHE-BERENGUER, Bernardo; LOZANO, Daniel; GUTIERREZ-ROJAS, Irene et al.Journal of endocrinology. 2011, Vol 209, Num 2, pp 203-210, issn 0022-0795, 8 p.Article

Exenatide : A new option for the treatment of type 2 diabetesBONG KYU YOO; TRILLER, Darren Michael; DONG JOO YOO et al.The Annals of pharmacotherapy. 2006, Vol 40, Num 10, pp 1777-1784, issn 1060-0280, 8 p.Article

Exénatide pour traiter le diabète de type 2 = Exenatide for type 2 diabetesThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 14, pp 71-72, issn 0253-8512, 2 p.Article

Effects of Exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesBUSE, John B; HENRY, Robert R; HAN, Jenny et al.Diabetes care. 2004, Vol 27, Num 11, pp 2628-2635, issn 0149-5992, 8 p.Article

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4KANOSKI, Scott E; FORTIN, Samantha M; ARNOLD, Myrtha et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3103-3112, issn 0013-7227, 10 p.Article

GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and HumansGIL-LOZANO, Manuel; PEREZ-TILVE, Diego; ALVAREZ-CRESPO, Mayte et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 6, pp 2629-2640, issn 0013-7227, 12 p.Article

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosisMARZIONI, M; ALPINI, G; SACCOMANNO, S et al.Gut. 2009, Vol 58, Num 7, pp 990-997, issn 0017-5749, 8 p.Article

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaKENDALL, David M; RIDDLE, Matthew C; ROSENSTOCK, Julio et al.Diabetes care. 2005, Vol 28, Num 5, pp 1083-1091, issn 0149-5992, 9 p.Article

Calcium/calmodulin-dependent serine protein kinase is involved in exendin-4-induced insulin secretion in INS-1 cellsZHU, Zheng-Qiu; DONG WANG; DAN XIANG et al.Metabolism, clinical and experimental. 2014, Vol 63, Num 1, pp 120-126, issn 0026-0495, 7 p.Article

Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behaviorANDERBERG, Rozita H; ANEFORS, Christine; BERGQUIST, Filip et al.Physiology & behavior. 2014, Vol 136, pp 135-144, issn 0031-9384, 10 p.Conference Paper

Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic ConnectivitySCHLOGL, Haiko; KABISCH, Stefan; STUMVOLL, Michael et al.Diabetes care. 2013, Vol 36, Num 7, pp 1933-1940, issn 0149-5992, 8 p.Article

Exendin-4 Protects Hypoxic Islets From Oxidative Stress and Improves Islet Transplantation OutcomePADMASEKAR, M; LINGWAL, N; SAMIKANNU, B et al.Endocrinology (Philadelphia). 2013, Vol 154, Num 4, pp 1424-1433, issn 0013-7227, 10 p.Article

Incretin hormones and the satiation signalHOLST, J. J.International journal of obesity. 2013, Vol 37, Num 9, pp 1161-1168, issn 0307-0565, 8 p.Article

Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 DiabetesHOROWITZ, Michael; RAYNER, Christopher K; JONES, Karen L et al.Advances in therapy. 2013, Vol 30, Num 2, pp 81-101, issn 0741-238X, 21 p.Article

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureasDAVIES, Melanie; HELLER, Simon; SREENAN MBBCH, Seamus et al.Diabetes care. 2013, Vol 36, Num 5, pp 1368-1376, issn 0149-5992, 9 p.Article

Effects of exenatide in poorly controlled type 2 diabetesKAIMAL, N; SCHOFIELD, J; ZAKI, A et al.QJM (Oxford. 1994. Print). 2012, Vol 105, Num 4, pp 321-326, issn 1460-2725, 6 p.Article

Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanismMING HAO; KUANG, Hong-Yu; ZHENG FU et al.Neurochemistry international. 2012, Vol 61, Num 1, pp 1-6, issn 0197-0186, 6 p.Article

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in miceTREVASKIS, James L; GRIFFIN, Peter S; WITTMER, Carrie et al.American journal of physiology. Gastrointestinal and liver physiology. 2012, Vol 65, Num 4, issn 0193-1857, G762-G772Article

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic miceTIMO RIEG; GERASIMOVA, Maria; MURRAY, Fiona et al.American journal of physiology. Renal physiology. 2012, Vol 72, Num 4, issn 1931-857X, F963-F971Article

Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell lineZHANG, Leshuai W; MCMAHON TOBIN, Grainne A; ROUSE, Rodney L et al.Toxicology and applied pharmacology. 2012, Vol 264, Num 2, pp 274-283, issn 0041-008X, 10 p.Article